Prof. Gongyan Chen 陈公琰
Chief Physician, Professor
Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of lung cancer, breast cancer, gastrointestinal tumors, malignant effusions, and malignant lymphoma using chemotherapy, endocrine therapy, and biological targeted therapy.
Dr. Chen is a Chief Physician and Professor with over 30 years of experience in medical oncology. Holding a medical doctorate from Harbin Medical University (graduated 1984), Dr. Chen focuses on lung cancer diagnosis, chemotherapy, and targeted therapy, including research on pathogenesis and multidrug resistance. Dr. Chen also treats breast cancer, gastrointestinal tumors, and lymphoma. Research achievements include establishing a patent for lung adenocarcinoma drug-resistant cell lines.
Professional roles
- Member, Lung Cancer Professional Committee, China Anti-Cancer Association
- Executive Committee Member, Chinese Society of Clinical Oncology (CSCO)
- Chair, Lung Cancer Professional Committee, Heilongjiang Gerontology Society
- Vice Chair, Chemotherapy Professional Committee, Heilongjiang Anti-Cancer Association
Name order: in Chinese the family name comes first (Chen Gongyan). Papers usually list the name as Gongyan Chen or Chen G.
Selected publications
68 papers on PubMed matched by name and affiliation; 3 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Cancer, 2020 (senior author): Clinical Characteristics Correlate With Outcomes of Immunotherapy in Advanced Non-Small Cell Lung Cancer. PubMed 33193876
- Clin Respir J, 2018 (senior author): The value of prognostic factors in Chinese patients with small cell lung cancer: A retrospective study of 999 patients. PubMed 27460525
- Onco Targets Ther, 2017 (senior author): CXCL12 suppresses cisplatin-induced apoptosis through activation of JAK2/STAT3 signaling in human non-small-cell lung cancer cells. PubMed 28721072
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion